Joseph R. Berger, MD, shares significant insights regarding neuromyelitis optica spectrum disorders (NMOSD) presented at the recent ECTRIMS conference. Key findings focused on the disease's ...
–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented –– 10-year ...
The US Food and Drug Administration (FDA) has approved the humanized monoclonal antibody eculizumab (Soliris, Alexion Pharmaceuticals) for the treatment of neuromyelitis optica spectrum disorder ...
– Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) – – Long-term safety ...
Immune cells must learn not to attack the body itself. A team of researchers from the Technical University of Munich (TUM) and the Ludwig Maximilian University of Munich (LMU) has discovered a ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback